Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 1, 2019
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
[ Fri, Nov 01st 2019
] - WOPRAI
Thu, October 31, 2019
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
[ Thu, Oct 31st 2019
] - WOPRAI
Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $250 on, Oct 31st, 2019
Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $240 to $250 on, Oct 31st, 2019.
Matthew has made no other calls on VRTX in the last 4 months.
There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alan Carr of "Needham" Downgraded from Strong Buy to Hold on, Thursday, August 1st, 2019
These are the ratings of the 3 analyists that currently disagree with Matthew
- Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $225 on, Tuesday, October 22nd, 2019
- Ying Huang of "B of A Securities" Initiated at Strong Buy and Held Target at $220 on, Thursday, October 17th, 2019
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $213 on, Thursday, August 1st, 2019
